Acular 0.5% w/v Eye Drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

acular 0.5% w/v eye drops, solution

abbvie limited - ketorolac trometamol - eye drops, solution - antiinflammatory agents, non-steroids; ketorolac

ACULAR OPHTHALMIC SOLUTION 0.5% Singapore - English - HSA (Health Sciences Authority)

acular ophthalmic solution 0.5%

abbvie pte. ltd. - ketorolac tromethamine - solution - 0.5% w/v - ketorolac tromethamine 0.5% w/v

Acular 0.5% w/v eye drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

acular 0.5% w/v eye drops, solution

imbat limited - ketorolac trometamol - eye drops, solution - 0.5 percent weight/volume - antiinflammatory agents, non-steroids; ketorolac

ACULAR 0.5% w/v Eye drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

acular 0.5% w/v eye drops, solution

pco manufacturing ltd. - ketorolac trometamol - eye drops, solution - 0.5 percent weight/volume - antiinflammatory agents, non-steroids; ketorolac

Acular 0.5% w/v Eye Drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

acular 0.5% w/v eye drops, solution

imed healthcare ltd. - ketorolac trometamol - eye drops, solution - antiinflammatory agents, non-steroids; ketorolac

ACULAR LS- ketorolac tromethamine solution/ drops United States - English - NLM (National Library of Medicine)

acular ls- ketorolac tromethamine solution/ drops

allergan, inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 4 mg in 1 ml - acular ls  ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.  acular ls ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation [see adverse reactions ( 6.1 )] . risk summary there are no adequate or well-controlled studies with acular ls in pregnant women. no evidence of teratogenicity has been observed in rats or rabbits with acular ls at clinically relevant doses. risk summary it is not known whether ketorolac when given topically is present in human milk. because many drugs are excreted in human milk, caution should be exercised when acular ls is administered to a nursing woman. safety and effectiveness of ketorolac tromethamine in pediatric patients below the age of 3 have not been established. no overall differences in safety or effectiveness have been observed between elderly and other adult patients.

ACULAR- ketorolac tromethamine solution/ drops United States - English - NLM (National Library of Medicine)

acular- ketorolac tromethamine solution/ drops

stat rx usa llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 5 mg in 1 ml - acular ® ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. acular ® ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. acular ® ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.

ACULAR- ketorolac tromethamine solution/ drops United States - English - NLM (National Library of Medicine)

acular- ketorolac tromethamine solution/ drops

allergan, inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - acular ® ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. acular ® ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. acular ® solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation. teratogenic effects.   pregnancy category c ketorolac tromethamine, administered during organogenesis, was not teratogenic in rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day, respectively. these doses are approximately 100 times and 250 times higher respectively than the maximum recommended human topical ophthalmic daily dose of 2 mg (5 mg/ml x 0.05 ml/drop, x 4 drops x 2 eyes) to affected eyes on a mg/kg basis. additionally, when administered to rats after day 17 of gestation at oral doses up to 1.5 mg/kg/day (approximately 40 times the typical human topical ophthalmic daily dos

Acular 0,4 % Namibia - English - Namibia Medicines Regulatory Council

acular 0,4 %

allergan pharmaceuticals (pty) ltd - ketorolac tromethamine - ophthalmic solution - acular 0,4 % ophthalmic solution contains ketorolac tromethamine 4 mg / ml

Yesafili European Union - English - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5.1),visual impairment due to diabetic macular oedema (dme) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.1).